Colorado Animal Specialty & Emergency (CASE)
The purpose of this study is to assess the safety and efficacy of a VLP NGF vaccine in client-owned dogs with naturally occurring osteoarthritis upon repeated immunization.
Screening Eligibility
Dogs ≥ 8 months with stable pain and lameness associated with osteoarthritis of at least one joint of the pelvic or thoracic limb lasting for at least 3 months
Lameness cannot be related to neoplasia, infection, immunologic or neurologic disease, or recent (less than 2 months) acute trauma.
Cannot have prior or current treatment with anti-NGF monoclonal antibodies (e.g,. Bedinvetmab (Librela))
Dogs cannot have shown visually notable weight loss or gain within a 6-week period before screening
Enrollment criteria
OA associated with at least one joint of the pelvic or thoracic limb
Benefits of Participation
Participating pet owners will receive:
Screening testing, including blood work, orthopedic examination, and x-ray examination, is all covered. Once enrolled, the study is fully funded, including adverse reactions to the vaccine. Owners will receive $100 at enrollment, $50 per scheduled visit, and $200 at study completion.
What to Expect
Participating patients will be required to complete standard pre-enrollment screening that involves a physical exam, orthopedic exam, lameness assessment, blood work, and radiographs. Dogs are seen for a total of 13 visits over the course of 203 days. Vaccine is administered only three times through the protocol with adverse effects monitored closely. Every visit will include a physical and orthopedic exam with lameness assessment and scores from owner(s) on how the dog is doing at home.
Pet Owner Resources
Interested?
Email: [email protected]
